Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
13vPnC vs 7vPnC in Healthy Infants in China
NCT01692886Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2012
- Primary completion
- Apr 2014
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised trial of pneumococcal 13-valent conjugate vaccine in pneumococcal infection (4 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 mcg/mL, Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody and 3 more. Started Sep 2012; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT01692886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01692886.